Lilly/Acrux's Axiron Delivers Testosterone Differently, But The Label Remains The Same
This article was originally published in The Pink Sheet Daily
Executive Summary
Newly-approved testosterone therapy product is delivered via the armpit, but FDA says the same precautions are necessary as for other products applied to the shoulders and upper arms.
You may also be interested in...
Endo's Fortesta To Join Crowded Testosterone Treatment Market In Q1
FDA approved the testosterone gel despite concerns about secondary exposure, but Fortesta will be competing against entrenched rivals and a new treatment from Eli Lilly.
Endo's Fortesta To Join Crowded Testosterone Treatment Market In Q1
FDA approved the testosterone gel despite concerns about secondary exposure, but Fortesta will be competing against entrenched rivals and a new treatment from Eli Lilly.
Deals Of The Week: Astellas/OSI, Pfizer/Tekmira, Teva/ratiopharm...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com